Sands Capital Alternatives, LLC
Sands Capital Alternatives, LLC reported 24 holdings worth US$614M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 13, 2026
Sands Capital Alternatives, LLC reported 24 holdings worth US$614M as of Jun 30, 2026. Largest: Alamar Biosciences, Inc., Nu Holdings Ltd. and Klaviyo, Inc. Series A. Filed Aug 13, 2026 (Form 13F).
- Holdings
- 24
- Value as reported
- US$614M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Alamar Biosciences, Inc. | 4.23M | US$115M | 18.7% |
| Nu Holdings Ltd. | 7.09M | US$94.8M | 15.4% |
| Klaviyo, Inc. Series A | 3.93M | US$59.3M | 9.7% |
| Beta Bionics, Inc. | 3.71M | US$58.1M | 9.5% |
| Spyglass Pharma, Inc. | 2.5M | US$55.7M | 9.1% |
| Inhibikase Therapeutics, Inc. | 13M | US$26.4M | 4.3% |
| Doordash, Inc. | 128K | US$23.5M | 3.8% |
| Coupang, Inc. | 1.33M | US$23.1M | 3.8% |
| Datadog, Inc. | 80,851 | US$21.1M | 3.4% |
| Bioage Labs, Inc. | 786K | US$19.3M | 3.1% |
| 10x Genomics, Inc. | 482K | US$18.5M | 3.0% |
| Samsara Inc. | 516K | US$16.7M | 2.7% |
| Odyssey Therapeutics, Inc. | 875K | US$16.4M | 2.7% |
| Toast, Inc. | 365K | US$10.2M | 1.7% |
| Acumen Pharmaceuticals, Inc. | 3.72M | US$9.93M | 1.6% |
| Servicetitan, Inc. | 109K | US$7.68M | 1.3% |
| Cerebras Systems Inc. | 32,825 | US$7.25M | 1.2% |
| Snowflake Inc. | 24,498 | US$6.23M | 1.0% |
| Tarsus Pharmaceuticals, Inc. | 85,000 | US$5.35M | 0.87% |
| Taysha Gene Therapies, Inc. | 725K | US$4.94M | 0.80% |
| Candel Therapeutics, Inc. | 406K | US$4.18M | 0.68% |
| Acrivon Therapeutics, Inc. | 2.29M | US$4.07M | 0.66% |
| Figma Inc | 22,165 | US$401K | 0.07% |